Wednesday, August 20, 2014 4:11:28 PM
LXRX- "It has two drugs in the late stages of development that still need FDA approval, without which the company will remain unprofitable. Morningstar equity analyst Karen Andersen estimates that each drug has a 60% chance of receiving approval."
Well, hurry up already!
Well, hurry up already!
Theo ;-)
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
